A more recent study also showed treatment of liposarcoma xenograft models with either the PI3K/AKT/mTOR pathway inhibitor rapamycin alone or in combination with the multi-kinase inhibitor sorafenib, all xenografts responded with increased lipid content and a more differentiated gene expression profile [34]. This evidence concerns the gene MTOR and liposarcoma.